nach oben

World Journal of Urology

Erschienen in:

18.07.2018 | Topic Paper

Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management

verfasst von: Jaime O. Herrera-Caceres, Antonio Finelli, Michael A. S. Jewett

Erschienen in: World Journal of Urology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Context

Renal tumor biopsy (RTB), as distinct from the more common renal biopsy for medical renal disease, is an option for patients with renal masses. It is mainly used for small renal masses (SRM) but it may also be indicated for larger masses and even in the presence of metastatic disease. Its main indication in SRM is to avoid intervention for benign kidney tumors but increasingly enables more personalized treatment for kidney cancer patients.

Objective

The objective of this paper is to provide a comprehensive review of the most recent literature available for RTB including the indications, the technique and also the possible complications.

Results

The urological community continues to optimize the indications for RTB. Non-operative treatment modalities, such as active surveillance, ablative modalities, and immunotherapy, may have different results influenced by tumor histology. Continuing concern regarding complications and accuracy and, therefore, the utility of RTB has been addressed. Recent reports support the potential benefit of RTB, safely avoiding a significant number of interventions with good results and minimal complications.

Conclusion

Urologists should be aware of the benefits of RTB and develop experience with this technique to optimize the results. This diagnostic strategy should be discussed with patients and adopted as it has been with other solid tumors.

Gill IS, Aron M, Gervais DA, Jewett MA (2010) Clinical practice. Small renal mass. N Engl J Med 362(7):624–634. https://doi.org/10.1056/NEJMcp0910041 CrossRefPubMed

Richard PO, Jewett MA, Bhatt JR, Kachura JR, Evans AJ, Zlotta AR, Hermanns T, Juvet T, Finelli A (2015) Renal tumor biopsy for small renal masses: a single-center 13-year experience. Eur Urol 68(6):1007–1013. https://doi.org/10.1016/j.eururo.2015.04.004 CrossRefPubMed

Osawa T, Hafez KS, Miller DC, Montgomery JS, Morgan TM, Palapattu GS, Weizer AZ, Caoili EM, Ellis JH, Kunju LP, Wolf JS Jr (2016) Age, gender and R.E.N.A.L. nephrometry score do not improve the accuracy of a risk stratification algorithm based on biopsy and mass size for assigning surveillance versus treatment of renal tumors. J Urol 195(3):574–580. https://doi.org/10.1016/j.juro.2015.10.137 CrossRefPubMed

Wells SA, Wong VK, Wittmann TA, Lubner MG, Best SL, Ziemlewicz TJ, Hinshaw JL, Lee FT Jr, Abel EJ (2017) Renal mass biopsy and thermal ablation: should biopsy be performed before or during the ablation procedure? Abdom Radiol (NY) 42(6):1773–1780. https://doi.org/10.1007/s00261-016-1037-8 CrossRef

Salem S, Ponsky LE, Abouassaly R, Cherullo EE, Isariyawongse JP, Maclennan GT, Nakamoto D, Haaga JR (2013) Image-guided biopsy of small renal masses in the era of ablative therapies. Int J Urol 20(6):580–584. https://doi.org/10.1111/iju.12010 CrossRefPubMed

Volpe A, Finelli A, Gill IS, Jewett MA, Martignoni G, Polascik TJ, Remzi M, Uzzo RG (2012) Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 62(3):491–504. https://doi.org/10.1016/j.eururo.2012.05.009 CrossRefPubMed

Huang H, Tamboli P, Karam JA, Vikram R, Zhang M (2016) Secondary malignancies diagnosed using kidney needle core biopsies: a clinical and pathological study of 75 cases. Hum Pathol 52:55–60. https://doi.org/10.1016/j.humpath.2015.12.028 CrossRefPubMed

Sanchez-Ortiz RF, Madsen LT, Bermejo CE, Wen S, Shen Y, Swanson DA, Wood CG (2004) A renal mass in the setting of a nonrenal malignancy: when is a renal tumor biopsy appropriate? Cancer 101(10):2195–2201. https://doi.org/10.1002/cncr.20638 CrossRefPubMed

Tomaszewski JJ, Uzzo RG, Smaldone MC (2014) Heterogeneity and renal mass biopsy: a review of its role and reliability. Cancer Biol Med 11(3):162–172. https://doi.org/10.7497/j.issn.2095-3941.2014.03.002 CrossRefPubMedPubMedCentral

10.

Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG (2010) Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol 184(5):1877–1881. https://doi.org/10.1016/j.juro.2010.06.105 CrossRefPubMedPubMedCentral

11.

Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659. https://doi.org/10.1056/NEJMoa003013 CrossRefPubMed

12.

Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for R, Treatment of Cancer Genitourinary G (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970CrossRefPubMed

13.

Leao RR, Richard PO, Jewett MA (2016) The role of biopsy for small renal masses. Int J Surg 36(Pt C):513–517. https://doi.org/10.1016/j.ijsu.2016.02.097 CrossRefPubMed

14.

Abel EJ, Carrasco A, Culp SH, Matin SF, Tamboli P, Tannir NM, Wood CG (2012) Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int 110(11):1742–1746. https://doi.org/10.1111/j.1464-410X.2012.11124.x CrossRefPubMed

15.

Abel EJ, Heckman JE, Hinshaw L, Best S, Lubner M, Jarrard DF, Downs TM, Nakada SY, Lee FT Jr, Huang W, Ziemlewicz T (2015) Multi-quadrant biopsy technique improves diagnostic ability in large heterogeneous renal masses. J Urol 194(4):886–891. https://doi.org/10.1016/j.juro.2015.03.106 CrossRefPubMed

16.

Nayan M, Richard PO, Jewett MA, Kachura JR, Evans A, Hamilton RJ, Finelli A (2016) Hematologic parameters to predict small renal mass biopsy pathology. Clin Genitourin Cancer 14(3):226–230. https://doi.org/10.1016/j.clgc.2015.12.007 CrossRefPubMed

17.

Tsivian M, Rampersaud EN Jr, del Pilar Laguna Pes M, Joniau S, Leveillee RJ, Shingleton WB, Aron M, Kim CY, DeMarzo AM, Desai MM, Meler JD, Donovan JF, Klingler HC, Sopko DR, Madden JF, Marberger M, Ferrandino MN, Polascik TJ (2014) Small renal mass biopsy—how, what and when: report from an international consensus panel. BJU Int 113(6):854–863. https://doi.org/10.1111/bju.12470 CrossRefPubMed

18.

Volpe A, Kachura JR, Geddie WR, Evans AJ, Gharajeh A, Saravanan A, Jewett MA (2007) Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol 178(2):379–386. https://doi.org/10.1016/j.juro.2007.03.131 CrossRefPubMed

19.

Muthuppalaniappan VM, Blunden MJ (2015) Renal biopsy. Medicine 43(7):395–398. https://doi.org/10.1016/j.mpmed.2015.04.013 CrossRef

20.

Breda A, Treat EG, Haft-Candell L, Leppert JT, Harper JD, Said J, Raman S, Smith RB, Belldegrun AS, Schulam PG (2010) Comparison of accuracy of 14-, 18- and 20-G needles in ex vivo renal mass biopsy: a prospective, blinded study. BJU Int 105(7):940–945. https://doi.org/10.1111/j.1464-410X.2009.08989.x CrossRefPubMed

21.

Shi GH, Chen Y, Yao XD, Zhang SL, Dai B, Feng LQ, Zhang HL, Shen YJ, Zhu Y, Zhu YP, Xiao WJ, Ma CG, Wen LG, Qin XJ, Yang LF, Ye DW (2013) Individualized renal mass biopsy strategy for Chinese patients with different subtypes and necrosis area. Urol Oncol 31(6):920–923. https://doi.org/10.1016/j.urolonc.2011.06.008 CrossRefPubMed

22.

Jay R, Heckman JE, Hinshaw L, Best S, Lubner M, Jarrard DF, Downs TM, Nakada SY, Lee FT, Huang W, Ziemlewicz T (2017) Multi-quadrant biopsy technique improves diagnostic ability in large heterogeneous renal masses. Abel EJ, Heckman JE, Hinshaw L, Best S, Lubner M, Jarrard DF, Downs TM, Nakada SY, Lee FT Jr, Huang W, Ziemlewicz T J Urol 2015 Oct;194(4):886-91. [Epub 2015 Mar 30]. https://doi.org/10.1016/j.juro.2015.03.106. Urol Oncol 35(3):119. https://doi.org/10.1016/j.urolonc.2016.12.025 CrossRefPubMed

23.

Dave CN, Seifman B, Chennamsetty A, Frontera R, Faraj K, Nelson R, Lucido C, Schervish EW (2017) Office-based ultrasound-guided renal core biopsy is safe and efficacious in the management of small renal masses. Urology 102:26–30. https://doi.org/10.1016/j.urology.2016.12.026 CrossRefPubMed

24.

Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K, Canfield SE, Hora M, Kuczyk MA, Merseburger AS, Mulders PF, Powles T, Staehler M, Ljungberg B, Volpe A (2016) Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 69(4):660–673. https://doi.org/10.1016/j.eururo.2015.07.072 CrossRefPubMed

25.

Yang CS, Choi E, Idrees MT, Chen S, Wu HH (2017) Percutaneous biopsy of the renal mass: FNA or core needle biopsy? Cancer Cytopathol 125(6):407–415. https://doi.org/10.1002/cncy.21852 CrossRefPubMed

26.

Curci N, Caoili EM (2017) The current role of biopsy in the diagnosis of renal tumors. Semin Ultrasound CT MR 38(1):72–77. https://doi.org/10.1053/j.sult.2016.09.003 CrossRefPubMed

27.

Patel HD, Johnson MH, Pierorazio PM, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME (2016) Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol 195(5):1340–1347. https://doi.org/10.1016/j.juro.2015.11.029 CrossRefPubMedPubMedCentral

28.

Remzi M, Marberger M (2009) Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? Eur Urol 55(2):359–367. https://doi.org/10.1016/j.eururo.2008.09.053 CrossRefPubMed

29.

Leveridge MJ, Finelli A, Kachura JR, Evans A, Chung H, Shiff DA, Fernandes K, Jewett MA (2011) Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 60(3):578–584. https://doi.org/10.1016/j.eururo.2011.06.021 CrossRefPubMed

30.

Rahbar H, Bhayani S, Stifelman M, Kaouk J, Allaf M, Marshall S, Zargar H, Ball MW, Larson J, Rogers C (2014) Evaluation of renal mass biopsy risk stratification algorithm for robotic partial nephrectomy—could a biopsy have guided management? J Urol 192(5):1337–1342. https://doi.org/10.1016/j.juro.2014.06.028 CrossRefPubMed

31.

Halverson SJ, Kunju LP, Bhalla R, Gadzinski AJ, Alderman M, Miller DC, Montgomery JS, Weizer AZ, Wu A, Hafez KS, Wolf JS Jr (2013) Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. J Urol 189(2):441–446. https://doi.org/10.1016/j.juro.2012.09.032 CrossRefPubMed

32.

Richard PO, Jewett MA, Tanguay S, Saarela O, Liu ZA, Pouliot F, Kapoor A, Rendon R, Finelli A (2017) Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. BJU Int 119(4):543–549. https://doi.org/10.1111/bju.13630 CrossRefPubMed

33.

Becker A, Hickmann D, Hansen J, Meyer C, Rink M, Schmid M, Eichelberg C, Strini K, Chromecki T, Jesche J, Regier M, Randazzo M, Tilki D, Ahyai S, Dahlem R, Fisch M, Zigeuner R, Chun FK (2016) Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma—impact on prognosis. Eur J Surg Oncol 42(3):419–425. https://doi.org/10.1016/j.ejso.2015.09.023 CrossRefPubMed

34.

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892. https://doi.org/10.1056/NEJMoa1113205 CrossRefPubMedPubMedCentral

35.

Ball MW, Bezerra SM, Gorin MA, Cowan M, Pavlovich CP, Pierorazio PM, Netto GJ, Allaf ME (2015) Grade heterogeneity in small renal masses: potential implications for renal mass biopsy. J Urol 193(1):36–40. https://doi.org/10.1016/j.juro.2014.06.067 CrossRefPubMed

36.

Ginzburg S, Uzzo R, Al-Saleem T, Dulaimi E, Walton J, Corcoran A, Plimack E, Mehrazin R, Tomaszewski J, Viterbo R, Chen DY, Greenberg R, Smaldone M, Kutikov A (2014) Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy. J Urol 191(2):296–300. https://doi.org/10.1016/j.juro.2013.07.059 CrossRefPubMed

37.

Patel HD, Druskin SC, Rowe SP, Pierorazio PM, Gorin MA, Allaf ME (2017) Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int 119(5):661–666. https://doi.org/10.1111/bju.13763 CrossRefPubMed

38.

Richard PO, Jewett MA, Bhatt JR, Evans AJ, Timilsina N, Finelli A (2016) Active surveillance for renal neoplasms with oncocytic features is safe. J Urol 195(3):581–586. https://doi.org/10.1016/j.juro.2015.09.067 CrossRefPubMed

39.

Prince J, Bultman E, Hinshaw L, Drewry A, Blute M, Best S, Lee FT Jr, Ziemlewicz T, Lubner M, Shi F, Nakada SY, Abel EJ (2015) Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. J Urol 193(6):1899–1904. https://doi.org/10.1016/j.juro.2014.12.021 CrossRefPubMed

40.

Jeon HG, Seo SI, Jeong BC, Jeon SS, Lee HM, Choi HY, Song C, Hong JH, Kim CS, Ahn H, Jeong IG (2016) Percutaneous kidney biopsy for a small renal mass: a critical appraisal of results. J Urol 195(3):568–573. https://doi.org/10.1016/j.juro.2015.09.073 CrossRefPubMed

41.

Ambani SN, Morgan TM, Montgomery JS, Gadzinski AJ, Jacobs BL, Hawken S, Krishnan N, Caoili EM, Ellis JH, Kunju LP, Hafez KS, Miller DC, Palapattu GS, Weizer AZ, Wolf JS Jr (2016) Predictors of delayed intervention for patients on active surveillance for small renal masses: does renal mass biopsy influence our decision? Urology 98:88–96. https://doi.org/10.1016/j.urology.2016.04.067 CrossRefPubMed

42.

Daugherty M, Sedaghatpour D, Shapiro O, Vourganti S, Kutikov A, Bratslavsky G (2017) The metastatic potential of renal tumors: influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. Urol Oncol 35(4):153.e115–153.e120. https://doi.org/10.1016/j.urolonc.2016.11.009 CrossRef

43.

Haifler M, Kutikov A (2017) Update on renal mass biopsy. Curr Urol Rep 18(4):28. https://doi.org/10.1007/s11934-017-0674-y CrossRefPubMed

44.

Wang Y, Chen YW, Leow JJ, Levy AC, Chang SL, Gelpi FH (2016) Cost-effectiveness of management options for small renal mass: a systematic review. Am J Clin Oncol 39(5):484–490. https://doi.org/10.1097/COC.0000000000000307 CrossRefPubMed

45.

Gorin MA, Rowe SP, Allaf ME (2016) Noninvasive determination of renal tumor histology utilizing molecular imaging. Urol Oncol 34(12):525–528. https://doi.org/10.1016/j.urolonc.2016.08.014 CrossRefPubMed

46.

Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, Chen D, Carrasquillo JA, Larson S, Bevan P, Russo P (2013) Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 31(2):187–194. https://doi.org/10.1200/JCO.2011.41.2445 CrossRefPubMed

47.

Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, Pavlovich CP, Epstein JI, Javadi MS, Allaf ME (2016) Prospective evaluation of (99m)Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol 69(3):413–416. https://doi.org/10.1016/j.eururo.2015.08.056 CrossRefPubMed

48.

Ball MW, Gorin MA, Bhayani SB, Rogers CG, Stifelman MD, Kaouk JH, Zargar H, Marshall S, Larson JA, Rahbar HM, Trock BJ, Pierorazio PM, Allaf ME (2015) Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis. Urol Oncol 33(3):112 e119–114. https://doi.org/10.1016/j.urolonc.2014.11.003 CrossRef

49.

Osawa T, Hafez KS, Miller DC, Montgomery JS, Morgan TM, Palapattu GS, Weizer AZ, Caoili EM, Ellis JH, Kunju LP, Wolf JS Jr (2016) Comparison of percutaneous renal mass biopsy and R.E.N.A.L. nephrometry score nomograms for determining benign vs malignant disease and low-risk vs high-risk renal tumors. Urology 96:87–92. https://doi.org/10.1016/j.urology.2016.05.044 CrossRefPubMed

50.

Canvasser NE, Kay FU, Xi Y, Pinho DF, Costa D, de Leon AD, Khatri G, Leyendecker JR, Yokoo T, Lay A, Kavoussi N, Koseoglu E, Cadeddu JA, Pedrosa I (2017) Diagnostic accuracy of multiparametric magnetic resonance imaging to identify clear cell renal cell carcinoma in cT1a renal masses. J Urol 198(4):780–786. https://doi.org/10.1016/j.juro.2017.04.089 CrossRefPubMedPubMedCentral

51.

Galmiche C, Bernhard JC, Yacoub M, Ravaud A, Grenier N, Cornelis F (2017) Is multiparametric MRI useful for differentiating oncocytomas from chromophobe renal cell carcinomas? AJR Am J Roentgenol 208(2):343–350. https://doi.org/10.2214/AJR.16.16832 CrossRefPubMed

52.

Kay FU, Canvasser NE, Xi Y, Pinho DF, Costa DN, Diaz de Leon A, Khatri G, Leyendecker JR, Yokoo T, Lay AH, Kavoussi N, Koseoglu E, Cadeddu JA, Pedrosa I (2018) Diagnostic performance and interreader agreement of a standardized mr imaging approach in the prediction of small renal mass histology. Radiology 287(2):543–553. https://doi.org/10.1148/radiol.2018171557 CrossRefPubMed

53.

Leao RR, Ahmad AE, Richard PO (2017) Should small renal masses be biopsied? Curr Urol Rep 18(1):7. https://doi.org/10.1007/s11934-017-0653-3 CrossRefPubMed

54.

Wan F, Zhu Y, Han C, Xu Q, Wu J, Dai B, Zhang H, Shi G, Gu W, Ye D (2017) Identification and validation of an eight-gene expression signature for predicting high Fuhrman grade renal cell carcinoma. Int J Cancer 140(5):1199–1208. https://doi.org/10.1002/ijc.30535 CrossRefPubMed

55.

Dong Y, Manley BJ, Becerra MF, Redzematovic A, Casuscelli J, Tennenbaum DM, Reznik E, Han S, Benfante N, Chen YB, Arcila ME, Aras O, Voss MH, Feldman DR, Motzer RJ, Fabbri N, Healey JH, Boland PJ, Chawla M, Durack JC, Lee CH, Coleman JA, Russo P, Hakimi AA, Cheng EH, Hsieh JJ (2016) Tumor xenografts of human clear cell renal cell carcinoma but not corresponding cell lines recapitulate clinical response to sunitinib: feasibility of using biopsy samples. Eur Urol Focus. https://doi.org/10.1016/j.euf.2016.08.005 CrossRefPubMedPubMedCentral

56.

Verbiest A, Couchy G, Job S, Zucman-Rossi J, Caruana L, Lerut E, Oyen R, de Reynies A, Laguerre B, Rioux-Leclercq N, Wozniak A, Joniau S, Van Poppel H, Van Den Eynde K, Beuselinck B (2017) Molecular subtypes of clear cell renal cell carcinoma are associated with outcome during pazopanib therapy in the metastatic setting. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2017.10.017 CrossRefPubMed

57.

Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ (2017) Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. J Pathol. https://doi.org/10.1002/path.5022 CrossRefPubMed

58.

Zurück zum Zitat Cancer genome atlas research n, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374(2):135–145. https://doi.org/10.1056/nejmoa1505917 CrossRef Cancer genome atlas research n, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374(2):135–145. https://doi.org/10.1056/nejmoa1505917 CrossRef

59.

Buvall L, Hedman H, Khramova A, Najar D, Bergwall L, Ebefors K, Sihlbom C, Lundstam S, Herrmann A, Wallentin H, Roos E, Nilsson UA, Johansson M, Tornell J, Haraldsson B, Nystrom J (2017) Orellanine specifically targets renal clear cell carcinoma. Oncotarget 8(53):91085–91098. https://doi.org/10.18632/oncotarget.19555 CrossRefPubMedPubMedCentral

60.

Kutikov A, Smaldone MC, Uzzo RG, Haifler M, Bratslavsky G, Leibovich BC (2016) Renal mass biopsy: always, sometimes, or never? Eur Urol 70(3):403–406. https://doi.org/10.1016/j.eururo.2016.04.001 CrossRefPubMed

61.

Richard PO, Martin L, Lavallee LT, Violette PD, Komisarenko M, Evans AJ, Jain K, Jewett MAS, Finelli A (2018) Identifying the use and barriers to the adoption of renal tumour biopsy in the management of small renal masses. Can Urol Assoc J. https://doi.org/10.5489/cuaj.5065 CrossRefPubMedPubMedCentral

62.

Richard PO, Lavallee LT, Pouliot F, Komisarenko M, Martin L, Latouff JB, Finelli A (2018) Is routine use of renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses? J Urol. https://doi.org/10.1016/j.juro.2018.04.015 CrossRefPubMed

Titel: Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management
verfasst von: Jaime O. Herrera-Caceres
Antonio Finelli
Michael A. S. Jewett
Publikationsdatum: 18.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 3/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2373-9

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management

Abstract

Context

Objective

Results

Conclusion

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Context

Objective

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Invasive non-urachal adenocarcinoma of the bladder: analysis of the National Cancer Database

Image-guided therapies for prostate and kidney cancers

Update on the ICUD-SIU consultation on multi-parametric magnetic resonance imaging in localised prostate cancer

“Three horse shoe-like incision” holmium laser enucleation of the prostate: first experience with a novel en bloc technique for anatomic transurethral prostatectomy

Surveillance after prostate focal therapy

Following the crowd: patterns of crowdsourcing on Twitter among urologists

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie